Early Response Assessment in Patients with Diffuse Large B-Cell Lymphoma Using 18-fluoro-2-deoxyglucose positron emission tomography (FDG-PET)

Study Status

Open to Enrollment

Study Description

Although many patients with diffuse large B cell lymphoma are cured with initial treatment, some patients do not respond well to therapy, or they relapse after an initial response. Certain factors have been shown to predict the probability of responding well, but they are not able to define whether an individual patient will respond well to treatment.

In this study, we are examining the ability of FDG-PET scanning early on in treatment to predict the ultimate outcome of that treatment in an individual patient. We hope to use the information gained in this study to individualize treatment in the future.

Patients will undergo 2 cycles of chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and predisone (R/CHOP). 14 to 21 days following Cycle 2 of R/CHOP, patients will undergo repeat FDG-PET scan (PET-2). They will then complete therapy as planned. Following completion of therapy, standard response assessments will be performed, including CT scans of the chest, abdomen, and pelvis and FDG-PET scan (PET-3).

Click here to visit our lymphoma blog.

Disease Status and/or Stage

Untreated CD20+ Diffuse Large B-Cell Lymphoma (DLBCL) of Any Stage


Weill Cornell Medical College

Key Eligibility

  • Men and women, age 18 and older
  • Histologically or cytologically confirmed diagnosis of CD20+ diffuse large B-cell lymphoma (DLBCL) of any stage, including subtypes:
    • Mediastinal large B-cell
    • Centroblastic
    • Immunoblastic
    • T-cell Rich B-cell Anaplastic B-cell lymphoma
  • No prior anti-lymphoma therapy
  • Patients must have a treatment plan to include R/CHOP or R/CHOP followed by radiotherapy

Principal Investigator

Rebecca Elstrom, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page